▟ Vinebot intrinsic value, daily

← back

PM Philip Morris International

consumer_staples · valued with opus medium conviction · deep-dived 2026-11-20

HOLD
Intrinsic value$144.03
Price (at call)$186.43
Margin of safety -22.7%
vs market (rating basis) +5.6%

Great transition franchise, but at $186 the market already pays for a smoke-free win.

The story

PMI is a global tobacco franchise in which high-margin combustible cigarettes, with pricing power and slowly falling volumes, fund the move to smoke-free products: IQOS heated tobacco, ZYN nicotine pouches and VEEV. Its moat rests on brands, regulatory barriers to entry, distribution scale and IQOS device lock-in. It is a mature cash machine with a second growth engine, now mid-transition: smoke-free products are approaching 40%+ of revenue and are lifting group margins as they scale.

I kept all drivers from my previous take because the facts support them and did not change materially. TTM revenue of $43.1B implies about 6-8% growth, in line with the 7% Y1 assumption. Operating margin has reached 39.9% TTM, so converging to 41% as smoke-free scales remains reasonable, not a peak. Sales-to-capital stays at 2.5 for incremental reinvestment because the reported 1.11 is inflated by acquisition goodwill (Swedish Match). The 10-year horizon reflects a durable but regulated franchise, and terminal growth of 3% sits below the risk-free rate.

Value drivers

Revenue growth (Y1)7.0%
Terminal growth3.0%
Forecast horizon10y
Target operating margin41.0%
Years to target margin5
Sales-to-capital2.50
Beta0.65
Failure probability1.0%
Cost of capital (WACC)7.6%
Terminal WACC9.0%

Valuation bridge

PV of explicit FCFF120.32B
PV of terminal value152.37B
Equity value224.49B
÷ shares → per share$144.03

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 46.16B 7.0% 40.1% 14.87B 1.21B 13.66B 12.69B
2 49.18B 6.6% 40.3% 15.93B 1.21B 14.72B 12.70B
3 52.19B 6.1% 40.6% 16.99B 1.20B 15.79B 12.66B
4 55.15B 5.7% 40.8% 18.05B 1.18B 16.87B 12.57B
5 58.03B 5.2% 41.0% 19.10B 1.15B 17.95B 12.42B
6 60.80B 4.8% 41.0% 20.01B 1.11B 18.90B 12.16B
7 63.43B 4.3% 41.0% 20.88B 1.05B 19.83B 11.84B
8 65.90B 3.9% 41.0% 21.69B 986.74M 20.70B 11.49B
9 68.17B 3.4% 41.0% 22.44B 907.96M 21.53B 11.10B
10 70.22B 3.0% 41.0% 23.11B 818.04M 22.29B 10.68B

Key risks

  • Regulatory or excise shocks to ZYN or IQOS (FDA flavor/nicotine caps, EU tobacco directive revisions, heated-tobacco tax parity)
  • Combustible volume declines accelerating faster than pricing can offset, plus FX drag from emerging-market currencies
  • High leverage ($44B net debt) and a payout-heavy dividend policy, which leave little room for missteps or rising rates

Catalysts

  • ZYN US capacity expansion and international rollout keeping smoke-free growth in the double digits
  • IQOS ILUMA US launch following FDA authorization, opening the largest profit pool

History

DatePriceIntrinsicMoSRating
2026-11-20$186.43 $144.03 -22.7% HOLD
2026-10-14$199.29 $136.28 -31.6% HOLD
2026-09-03$187.94 $111.28 -40.8% HOLD
2026-07-27$193.00 $113.32 -41.3% HOLD
2026-06-23$178.69 $121.37 -32.1% BUY